Research
Hormonal
Combining GLP-1 RAs with EBTs may yield synergistic effects.
Practitioners may explore combination therapies for enhanced weight loss outcomes.
GoodSupportsmedium confidence
Emerging data suggest that combining GLP-1 RAs with EBTs may yield synergistic effects.
Why this rating
The claim is based on emerging data, suggesting a developing area of research.
Source
Endobariatrics in the era of glucagon-like peptide-1 receptor agonists: evolving roles, evidence, and integration
Farnoosh Vahedi et al. · Current Opinion in Gastroenterology · 2025
DOI 10.1097/mog.0000000000001134
review
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →